Beliefs about medications predict adherence to antidepressants in older adults

2011 ◽  
Vol 24 (1) ◽  
pp. 159-169 ◽  
Author(s):  
Waleed Fawzi ◽  
Mohamed Yousry Abdel Mohsen ◽  
Abdel Hamid Hashem ◽  
Suaad Moussa ◽  
Elizabeth Coker ◽  
...  
Keyword(s):  
Side Effects ◽  
Rating Scale ◽  
Poor Response ◽  
Self Report ◽  
Poor Adherence ◽  
Response To Treatment ◽  
Medication Side Effects ◽  
Beliefs About Medicines ◽  
Medication Side ◽  
Highly Correlated

ABSTRACTBackground: Adherence to treatment is a complex and poorly understood phenomenon. This study investigates the relationship between older depressed patients’ adherence to antidepressants and their beliefs about and knowledge of the medication.Methods: Assessment was undertaken of 108 outpatients over the age of 55 years diagnosed with depressive disorder and treated for at least four weeks with antidepressants. Adherence was assessed using two self-report measures: the Medication Adherence Rating Scale (MARS) and a Global Adherence Measure (GAM). Potential predictors of adherence investigated included sociodemographic, medication and illness variables. In addition, 33 carers were interviewed regarding general medication beliefs.Results: 56% of patients reported 80% or higher adherence on the GAM. Sociodemographic variables were not associated with adherence on the MARS. Specific beliefs about medicines, such as “my health depends on antidepressants” (necessity) and being less worried about becoming dependant on antidepressants (concern) were highly correlated with adherence. General beliefs about medicines causing harm or being overprescribed, experiencing medication side-effects and severity of depression also correlated with poor adherence. Linear regression with the MARS as the dependent variable explained 44.3% of the variance and showed adherence to be higher in subjects with healthy specific beliefs who received more information about antidepressants and worse with depression severity and autonomic side-effects.Conclusions: Our findings strongly support a role for specific beliefs about medicines in adherence. Challenging patients’ beliefs, providing information about treatment and discussing side-effects could improve adherence. Poor response to treatment and medication side-effects can indicate poor adherence and should be considered before switching medications.

Enhancing Case Managers' Skills in the Assessment and Management of Antipsychotic Medication Side-Effects

2000 ◽  
Vol 34 (5) ◽  
pp. 814-821 ◽  
Author(s):  
Paul Morrison ◽  
Tom Meehan ◽  
Deanne Gaskill ◽  
Paul Lunney ◽  
Paul Collings
Keyword(s):  
Side Effects ◽  
Training Program ◽  
Antipsychotic Medication ◽  
Side Effect ◽  
Rating Scale ◽  
Intervention Group ◽  
Case Managers ◽  
Short Term ◽  
Medication Side Effects ◽  
Medication Side

Objective: Our goal was to reduce the prevalence of antipsychotic medication side-effects by providing a short-term training program on the assessment and management of side-effects to case managers. Method: Forty-four patients in receipt of community-based mental health services were allocated to comparison (n = 20) and intervention (n = 24) groups based on the health service district in which they resided. While case managers working with the intervention group attended a short-term training program to improve their assessment and management of neuroleptic side-effects, case managers providing services to the comparison group received no additional training. Side-effects were assessed pre- and postintervention using the Liverpool University Neuroleptic Side-effect Rating Scale (LUNSERS). Results: A reduction in the overall prevalence of side-effects in both groups was observed, however, only those patients in the intervention group reported a statistically significant reduction in mean side-effect scores between the pre- and post-measures (Wilcoxon Matched Pairs Signed-ranks Test, z = −2.8411, two-tailed, p < 0.01). In addition, qualitative data collected during the second survey revealed that patients in the intervention group had acquired some positive management strategies for dealing with unwanted side-effects. The strategies were elicited from eight different patients distributed across six of the 12 case managers who took part in the training program. Conclusions: Training cases managers in the assessment and management of side-effects may help to reduce their impact on the lives of people prescribed neuroleptic medication.

Univariate and Multivariate Base Rates of Score Elevations, Reliable Change, and Inter-Rater Discrepancies in the BRIEF-A Standardization Samples

Assessment ◽  
2021 ◽  
pp. 107319112110556
Author(s):  
Stephen L. Aita ◽  
Grant G. Moncrief ◽  
Jennifer Greene ◽  
Sue Trujillo ◽  
Alicia Carrillo ◽  
...  
Keyword(s):  
Rating Scale ◽  
Self Report ◽  
Behavior Rating ◽  
Reliable Change ◽  
Informant Report ◽  
Base Rates ◽  
T Score ◽  
Behavior Rating Inventory ◽  
The Common ◽  
Highly Correlated

The Behavior Rating Inventory of Executive Function–Adult Version (BRIEF-A) is a standardized rating scale of subjective executive functioning. We provide univariate and multivariate base rates (BRs) for scale/index scores in the clinical range ( T scores ≥65), reliable change, and inter-rater information not included in the Professional Manual. Participants were adults (ages = 18–90 years) from the BRIEF-A self-report ( N = 1,050) and informant report ( N = 1,200) standardization samples, as well as test–retest ( n = 50 for self, n = 44 for informant) and inter-rater ( n = 180) samples. Univariate BRs of elevated T scores were low (self-report = 3.3%–15.4%, informant report = 4.5%–16.3%). Multivariate BRs revealed the common occurrence of obtaining at least one elevated T-score across scales (self-report = 26.5%–37.3%, informant report = 22.7%–30.3%), whereas virtually none had elevated scores on all scales. Test–retest scores were highly correlated (self = .82–.94; informant = .91–.96). Inter-rater correlations ranged from .44 to .68. Significant ( p < .05) test–retest T-score differences ranged from 7 to 12 for self-report, from 6 to 8 for informant report, and from 16 to 21 points for inter-rater T-score differences. Applications of these findings are discussed.

Medication side effects

BMJ ◽  
2010 ◽  
Vol 341 (sep15 2) ◽  
pp. c4999-c4999
Keyword(s):  
Side Effects ◽  
Medication Side Effects ◽  
Medication Side

scholarly journals Cutaneous Effects of Notch Inhibitor Therapy: A Report of Two Cases

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Claire J. Wiggins ◽  
Susan Y. Chon
Keyword(s):  
Side Effects ◽  
Notch Signaling ◽  
Hidradenitis Suppurativa ◽  
Disease Pathogenesis ◽  
Cutaneous Side Effects ◽  
Medication Side Effects ◽  
Medication Side ◽  
Notch Pathways ◽  
Inhibitor Treatment

As aberrant Notch signaling has been linked to cancerous growth, Notch inhibitors represent a novel category of targeted oncological therapy. Notch pathways in tumor cells may contribute to proliferation or limit apoptosis and differentiation. Healthy skin differentiation and homeostasis are reliant on normal Notch expression, and disruption of this signaling has been implicated in dermatological conditions such as hidradenitis suppurativa, psoriasis, atopic dermatitis, and lichen planus. Here, we describe two cases of patients with cutaneous side effects from Notch inhibitor treatment for adenoid cyst carcinoma (ACC) and review the role of Notch signaling in skin disease. By illuminating connections between medication side effects and disease pathogenesis, our goal is to increase awareness of the cutaneous side effects of Notch inhibitor treatment.

Sign in / Sign up

Export Citation Format

Share Document